XFOR
XFOR
NASDAQ · Biotechnology

X4 Pharmaceuticals Inc

$4.12
-0.16 (-3.74%)
As of Mar 23, 3:46 PM ET ·
Financial Highlights (FY 2026)
Revenue
36.69M
Net Income
-537,342,141
Gross Margin
68.8%
Profit Margin
-1,464.6%
Rev Growth
-5.2%
D/E Ratio
3.41
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 68.8% 68.8% 43.0% 43.0%
Operating Margin -1,423.6% -1,281.2% 20.9% 17.6%
Profit Margin -1,464.6% -1,391.4% 16.3% 17.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 36.69M 38.69M 57.05M 55.03M
Gross Profit 25.25M 26.63M 24.51M 23.64M
Operating Income -522,259,640 -495,763,818 11.90M 9.71M
Net Income -537,342,141 -510,081,137 9.29M 9.37M
Gross Margin 68.8% 68.8% 43.0% 43.0%
Operating Margin -1,423.6% -1,281.2% 20.9% 17.6%
Profit Margin -1,464.6% -1,391.4% 16.3% 17.0%
Rev Growth -5.2% -5.2% +3.4% -0.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 114.10M 114.10M 127.66M 98.88M
Total Equity 33.51M 33.51M 135.98M 129.32M
D/E Ratio 3.41 3.41 0.94 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -478,442,026 -479,400,827 17.50M 15.80M
Free Cash Flow 7.43M 8.43M